{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:17:08Z","timestamp":1791515828531,"version":"4.3.4"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>BH3-mimetics are a novel drug class of small molecule inhibitors of BCL2 family proteins which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the selective BCL2 inhibitor venetoclax, is highly efficacious in chronic lymphocytic leukemia and has rapidly advanced to an approved standard of care in frontline and relapsed disease in combination with anti-CD20 monoclonal antibodies. In this context, tumour lysis syndrome and myelosuppression are the most commonly encountered\u00a0toxicities and are readily manageable with established protocols.\u00a0Venetoclax is active in other lymphoid malignancies including several B cell non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, with the highest intrinsic sensitivity observed in mantle cell lymphoma and Waldenstrom macroglobulinemia. Venetoclax combination with standard regimens in follicular lymphoma, multiple myeloma and aggressive B cell neoplasms has shown some promise, but further studies are required to optimize dose and scheduling to mitigate increased myelosuppression\u00a0and infection risk, and to find validated biomarkers of venetoclax sensitivity. Future research will focus on overcoming venetoclax resistance, targeting other BCL2 family members and the rational design of synergistic combinations.<\/jats:p>","DOI":"10.1186\/s13045-022-01295-3","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:03:45Z","timestamp":1654250625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2432","authenticated-orcid":false,"given":"Thomas E.","family":"Lew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6835","authenticated-orcid":false,"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"issue":"9","key":"1295_CR1","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"S Cory","year":"2002","unstructured":"Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647\u201356.","journal-title":"Nat Rev Cancer"},{"issue":"6189","key":"1295_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/335440a0","volume":"335","author":"DL Vaux","year":"1988","unstructured":"Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335(6189):440\u20132.","journal-title":"Nature"},{"issue":"2","key":"1295_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrc.2015.17","volume":"16","author":"AR Delbridge","year":"2016","unstructured":"Delbridge AR, Grabow S, Strasser A, Vaux DL. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16(2):99\u2013109.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1295_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2008.07353.x","volume":"143","author":"B Pro","year":"2008","unstructured":"Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008;143(3):355\u201360.","journal-title":"Br J Haematol"},{"issue":"30","key":"1295_CR5","doi-asserted-by":"publisher","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","volume":"23","author":"SM O'Brien","year":"2005","unstructured":"O\u2019Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23(30):7697\u2013702.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1295_CR6","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1200\/JCO.2009.22.5748","volume":"27","author":"S O'Brien","year":"2009","unstructured":"O\u2019Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol. 2009;27(31):5208\u201312.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1295_CR7","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-08-0144","volume":"15","author":"MH Kang","year":"2009","unstructured":"Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009;15(4):1126\u201332.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1295_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","volume":"34","author":"D Merino","year":"2018","unstructured":"Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell. 2018;34(6):879\u201391.","journal-title":"Cancer Cell"},{"issue":"2","key":"1295_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"1295_CR10","first-page":"456","volume":"10","author":"LE Robertson","year":"1996","unstructured":"Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10(3):456\u20139.","journal-title":"Leukemia"},{"issue":"4","key":"1295_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"1295_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1182\/bloodadvances.2019000864","volume":"4","author":"TE Lew","year":"2020","unstructured":"Lew TE, Anderson MA, Lin VS, Handunnetti SM, Came NA, Blombery P, et al. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Adv. 2020;4(1):165\u201373.","journal-title":"Blood Adv"},{"issue":"3","key":"1295_CR13","first-page":"415","volume":"3","author":"TE Lew","year":"2020","unstructured":"Lew TE, Anderson MA, Seymour JF. Promises and pitfalls of targeted agents in chronic lymphocytic leukemia. Cancer Drug Res. 2020;3(3):415\u201344.","journal-title":"Cancer Drug Res"},{"key":"1295_CR14","doi-asserted-by":"publisher","first-page":"789891","DOI":"10.3389\/fonc.2021.789891","volume":"11","author":"L Ballotta","year":"2021","unstructured":"Ballotta L, Zinzani PL, Pileri S, Bruna R, Tani M, Casadei B, et al. Venetoclax shows low therapeutic activity in BCL2-positive relapsed\/refractory peripheral T-Cell lymphoma: a phase 2 study of the fondazione italiana linfomi. Front Oncol. 2021;11:789891.","journal-title":"Front Oncol"},{"issue":"5","key":"1295_CR15","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488\u201396.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1295_CR16","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173\u201386.","journal-title":"Cell"},{"issue":"2","key":"1295_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","volume":"113","author":"SM O'Brien","year":"2009","unstructured":"O\u2019Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009;113(2):299\u2013305.","journal-title":"Blood"},{"issue":"15","key":"1295_CR18","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-10-0822","volume":"16","author":"JJ Hwang","year":"2010","unstructured":"Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL, et al. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res. 2010;16(15):4038\u201345.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1295_CR19","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.clml.2019.09.081","volume":"19","author":"A Spencer","year":"2019","unstructured":"Spencer A, Rosenberg AS, Jakubowiak A, Raje N, Chatterjee M, Trudel S, et al. A phase 1, first-in-human study of AMG 176, a selective MCL-1 inhibitor, in patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(10):e53\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1295_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/hon.85_2881","author":"C Cheah","year":"2021","unstructured":"Cheah C, Verner E, Tam C, Hilger J, Gao Y, Huang J, et al. Preliminary safety data from patients with relapsed\/refractory B-cell malignancies treated with the novel B-cell lymphoma (BCL2) inhibitor BGB-11417. Hematol Oncol. 2021. https:\/\/doi.org\/10.1002\/hon.85_2881.","journal-title":"Hematol Oncol."},{"issue":"15","key":"1295_CR21","doi-asserted-by":"publisher","first-page":"7502","DOI":"10.1200\/JCO.2021.39.15_suppl.7502","volume":"39","author":"S Ailawadhi","year":"2021","unstructured":"Ailawadhi S, Chanan-Khan AAA, Chen Z, Huang B, Konopleva M, Brander DM, et al. First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed\/refractory (R\/R) CLL and other hematologic malignancies (HMs). J Clin Oncol. 2021;39(15):7502.","journal-title":"J Clin Oncol."},{"issue":"Suppl 1","key":"1295_CR22","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood-2021-148451","volume":"138","author":"CS Tam","year":"2021","unstructured":"Tam CS, Verner E, Lasica M, Arbelaez A, Browett PJ, Soumerai JD, et al. Preliminary safety and efficacy data from patients (Pts) with relapsed\/refractory (R\/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with Zanubrutinib. Blood. 2021;138(Suppl 1):1419.","journal-title":"Blood."},{"issue":"Suppl 1","key":"1295_CR23","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1182\/blood-2021-152235","volume":"138","author":"M Sun","year":"2021","unstructured":"Sun M, Qi J, Chen Z, Zhang H, Song Y, Shen A, et al. A Phase 1 study to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with certain relapsed or refractory (R\/R) hematologic malignancies (HMs). Blood. 2021;138(Suppl 1):3730.","journal-title":"Blood."},{"issue":"13","key":"1295_CR24","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138(13):1120\u201336.","journal-title":"Blood"},{"issue":"2","key":"1295_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","volume":"18","author":"JF Seymour","year":"2017","unstructured":"Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230\u201340.","journal-title":"Lancet Oncol"},{"issue":"18","key":"1295_CR26","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","volume":"24","author":"MS Davids","year":"2018","unstructured":"Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24(18):4371\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1295_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/hematology.2020000120","volume":"2020","author":"K Fischer","year":"2020","unstructured":"Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2020;2020(1):357\u201362.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"1295_CR28","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188\u2013200.","journal-title":"Lancet Oncol"},{"issue":"22","key":"1295_CR29","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095\u2013103.","journal-title":"N Engl J Med"},{"issue":"26","key":"1295_CR30","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1182\/blood-2019-01-896290","volume":"133","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed\/refractory chronic lymphocytic leukemia. Blood. 2019;133(26):2765\u201375.","journal-title":"Blood"},{"issue":"23","key":"1295_CR31","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225\u201336.","journal-title":"N Engl J Med"},{"issue":"12","key":"1295_CR32","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107\u201320.","journal-title":"N Engl J Med"},{"key":"1295_CR33","unstructured":"AbbVie. Venclexta (Venetoclax) Tablets Full Prescribing Information. 2016."},{"key":"1295_CR34","doi-asserted-by":"publisher","first-page":"Jco1800359","DOI":"10.1200\/JCO.18.00359","volume":"36","author":"MS Davids","year":"2018","unstructured":"Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, et al. Revised dose ramp-up to mitigate the risk of tumor lysis syndrome when initiating venetoclax in patients with mantle cell lymphoma. J Clin Oncol. 2018;36:Jco1800359.","journal-title":"J Clin Oncol."},{"issue":"8","key":"1295_CR35","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333.","journal-title":"J Clin Oncol"},{"issue":"279","key":"1295_CR36","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7(279):279ra40.","journal-title":"Sci Transl Med."},{"key":"1295_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3324\/haematol.2020.266486","volume":"107","author":"AR Mato","year":"2020","unstructured":"Mato AR, Sharman JP, Biondo JML, Wu M, Mun Y, Kim SY, et al. The impact of early discontinuation\/dose modification of venetoclax on outcomes in patients with relapsed\/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study. Haematologica. 2020;107:134\u201342.","journal-title":"Haematologica."},{"issue":"17","key":"1295_CR38","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","volume":"27","author":"MS Davids","year":"2021","unstructured":"Davids MS, Roberts AW, Kenkre VP, Wierda WG, Kumar A, Kipps TJ, et al. Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I, First-in-Human study. Clin Cancer Res. 2021;27(17):4690\u20135.","journal-title":"Clin Cancer Res"},{"key":"1295_CR39","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1182\/blood.2021012775","volume":"139","author":"P Blombery","year":"2021","unstructured":"Blombery P, Lew TE, Dengler MA, Thompson ER, Lin VS, Chen X, et al. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood. 2021;139:1198\u2013207.","journal-title":"Blood."},{"issue":"3","key":"1295_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1208\/s12249-021-01968-1","volume":"22","author":"SG Kala","year":"2021","unstructured":"Kala SG, Chinni S. Development and characterization of venetoclax nanocrystals for oral bioavailability enhancement. AAPS PharmSciTech. 2021;22(3):92.","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"1295_CR41","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/1535-7163.MCT-21-0077","volume":"20","author":"AH Salem","year":"2021","unstructured":"Salem AH, Tao ZF, Bueno OF, Chen J, Chen S, Edalji R, et al. Expanding the repertoire for \u201cLarge small molecules\u201d: prodrug abbv-167 efficiently converts to venetoclax with reduced food effect in healthy volunteers. Mol Cancer Ther. 2021;20(6):999\u20131008.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"1295_CR42","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","volume":"56","author":"TJ Kipps","year":"2015","unstructured":"Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(10):2826\u201333.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1295_CR43","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bjh.13487","volume":"170","author":"AW Roberts","year":"2015","unstructured":"Roberts AW, Advani RH, Kahl BS, Persky D, Sweetenham JW, Carney DA, et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol. 2015;170(5):669\u201378.","journal-title":"Br J Haematol"},{"issue":"2","key":"1295_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood.2018882555","volume":"134","author":"AW Roberts","year":"2019","unstructured":"Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019;134(2):111\u201322.","journal-title":"Blood"},{"issue":"12","key":"1295_CR45","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149\u201359.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1295_CR46","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/10428194.2020.1845332","volume":"62","author":"S de Vos","year":"2021","unstructured":"de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, et al. Safety and efficacy of navitoclax, a BCL-2 and BCL-X(L) inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leuk Lymphoma. 2021;62(4):810\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1295_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25(1):119\u201329.","journal-title":"Nat Med"},{"issue":"3","key":"1295_CR48","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the recurrent GLY101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342\u201353.","journal-title":"Cancer Discov"},{"issue":"24","key":"1295_CR49","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","volume":"26","author":"SB Balachander","year":"2020","unstructured":"Balachander SB, Criscione SW, Byth KF, Cidado J, Adam A, Lewis P, et al. AZD4320, A dual inhibitor of Bcl-2 and Bcl-x(L), induces tumor regression in hematologic cancer models without dose-limiting thrombocytopenia. Clin Cancer Res. 2020;26(24):6535\u201349.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1295_CR50","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440\u201353.","journal-title":"Cancer Discov"},{"issue":"6","key":"1295_CR51","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768\u201378.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1295_CR52","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","volume":"36","author":"S Stilgenbauer","year":"2018","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973\u201380.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1295_CR53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342.","journal-title":"N Engl J Med"},{"issue":"11","key":"1295_CR54","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997\u20131007.","journal-title":"N Engl J Med"},{"issue":"15","key":"1295_CR55","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","volume":"131","author":"S Coutre","year":"2018","unstructured":"Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018;131(15):1704\u201311.","journal-title":"Blood"},{"issue":"1","key":"1295_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","volume":"19","author":"JA Jones","year":"2018","unstructured":"Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65\u201375.","journal-title":"Lancet Oncol"},{"key":"1295_CR57","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1080\/10428194.2021.1986217","volume":"63","author":"T Cochrane","year":"2021","unstructured":"Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, et al. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. Leuk Lymphoma. 2021;63:304\u201314.","journal-title":"Leuk Lymphoma."},{"issue":"10","key":"1295_CR58","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/blood.2020009578","volume":"138","author":"S Ma","year":"2021","unstructured":"Ma S, Seymour JF, Brander DM, Kipps TJ, Choi MY, Anderson MA, et al. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood. 2021;138(10):836\u201346.","journal-title":"Blood"},{"issue":"9","key":"1295_CR59","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S1470-2045(18)30414-5","volume":"19","author":"P Cramer","year":"2018","unstructured":"Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(9):1215\u201328.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"1295_CR60","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2021-147258","volume":"138","author":"IW Flinn","year":"2021","unstructured":"Flinn IW, Andorsky D, Melear J, Manda S, Anz B III, Kolibaba K, et al. Debulking before initiation of venetoclax therapy in untreated patients with chronic lymphocytic leukemia: results from a phase 3b study. Blood. 2021;138(Suppl 1):3725.","journal-title":"Blood."},{"issue":"30","key":"1295_CR61","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen P, Rawstron AC, Brock K, Munoz-Vicente S, Yates FJ, Bishop R, et al. Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: The CLARITY study. J Clin Oncol. 2019;37(30):2722\u20139.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1295_CR62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-136109","volume":"136","author":"AP Kater","year":"2020","unstructured":"Kater AP, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Owen C, et al. Five-year analysis of murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL) patients (Pts) following fixed-duration venetoclax-rituximab (VenR) therapy (Tx). Blood. 2020;136(Supplement 1):19\u201321.","journal-title":"Blood"},{"issue":"4","key":"1295_CR63","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the Murano phase III study. J Clin Oncol. 2019;37(4):269\u201377.","journal-title":"J Clin Oncol"},{"key":"1295_CR64","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.20.00948","volume":"38","author":"AP Kater","year":"2020","unstructured":"Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D\u2019Rozario J, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the murano phase III study. J Clin Oncol. 2020;38:4042\u201354.","journal-title":"J Clin Oncol."},{"issue":"Suppl 1","key":"1295_CR65","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood-2019-125825","volume":"134","author":"K Fischer","year":"2019","unstructured":"Fischer K, Ritgen M, Al-Sawaf O, Robrecht S, Tandon M, Fink A-M, et al. Quantitative analysis of minimal residual disease (MRD) shows high rates of undetectable mrd after fixed-duration chemotherapy-free treatment and serves as surrogate marker for progression-free survival: a prospective analysis of the randomized CLL14 trial. Blood. 2019;134(Suppl 1):36.","journal-title":"Blood."},{"issue":"8","key":"1295_CR66","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3324\/haematol.2014.104661","volume":"99","author":"P Strati","year":"2014","unstructured":"Strati P, Keating MJ, O\u2019Brien SM, Ferrajoli A, Burger J, Faderl S, et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014;99(8):1350\u20135.","journal-title":"Haematologica"},{"issue":"5","key":"1295_CR67","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, et al. Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432\u201343.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1295_CR68","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2021-146161","volume":"138","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Niemann C, Kater AP, F\u00fcrstenau M, Von Tresckow J, Zhang C, et al. A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR\/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: first co-primary endpoint analysis of the international intergroup GAIA (CLL13) Trial. Blood. 2021;138(Suppl 1):71.","journal-title":"Blood."},{"issue":"3","key":"1295_CR69","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Tam CS, O\u2019Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1295_CR70","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood-2020-137415","volume":"136","author":"RA Harrup","year":"2020","unstructured":"Harrup RA, Owen C, D\u2019Rozario J, Robak T, Kater AP, Montillo M, et al. Efficacy of subsequent novel targeted therapies, including repeated Venetoclax-Rituximab (VenR), in patients (Pts) with relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL) previously treated with fixed-duration venr in the Murano study. Blood. 2020;136(Supplement 1):44\u20135.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1295_CR71","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-138725","volume":"136","author":"MC Thompson","year":"2020","unstructured":"Thompson MC, Allan JN, Sail K, Manzoor BS, Pu JJ, Barr PM, et al. Venetoclax Re-treatment of chronic lymphocytic leukemia (CLL) patients after a previous Venetoclax-based regimen. Blood. 2020;136(Supplement 1):39\u201341.","journal-title":"Blood"},{"key":"1295_CR72","doi-asserted-by":"crossref","unstructured":"Wu JQ, Seymour JF, Eichhorst B, Hillmen P, Kipps T, Langerak AW, et al. Unfavourable genetics impact MRD response to venetoclax+rituximab retreatment in relapsed or refractory chronic lymphocytic leukemia: phase 3 MURANO substudy Haematol Oncol. 2021;39(S2).","DOI":"10.1002\/hon.50_2880"},{"issue":"5","key":"1295_CR73","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1182\/blood.2020008502","volume":"138","author":"TE Lew","year":"2021","unstructured":"Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. Blood. 2021;138(5):361\u20139.","journal-title":"Blood"},{"issue":"20","key":"1295_CR74","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","volume":"5","author":"TE Lew","year":"2021","unstructured":"Lew TE, Lin VS, Cliff ER, Blombery P, Thompson ER, Handunnetti SM, et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Adv. 2021;5(20):4054\u20138.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"1295_CR75","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood-2021-153033","volume":"138","author":"MS Davids","year":"2021","unstructured":"Davids MS, Fischer K, Robrecht S, Zhang C, Ahn IE, Porro Lur\u00e0 M, et al. ReVenG: a phase 2 study of venetoclax plus obinutuzumab retreatment in patients with relapsed chronic lymphocytic leukemia. Blood. 2021;138(Supplement 1):2634.","journal-title":"Blood."},{"issue":"48","key":"1295_CR76","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.1038\/onc.2016.155","volume":"35","author":"Y Li","year":"2016","unstructured":"Li Y, Bouchlaka MN, Wolff J, Grindle KM, Lu L, Qian S, et al. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene. 2016;35(48):6223\u201334.","journal-title":"Oncogene"},{"issue":"18","key":"1295_CR77","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.1158\/1078-0432.CCR-11-0955","volume":"17","author":"C Touzeau","year":"2011","unstructured":"Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A, et al. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high\/Mcl-1low profile and synergizes with other antineoplastic agents. Clin Cancer Res. 2011;17(18):5973\u201381.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1295_CR78","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211\u201323.","journal-title":"N Engl J Med"},{"issue":"2","key":"1295_CR79","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68\u201371.","journal-title":"Haematologica"},{"issue":"6","key":"1295_CR80","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.25796","volume":"95","author":"S Zhao","year":"2020","unstructured":"Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL)\u2014outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95(6):623\u20139.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"1295_CR81","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-138878","volume":"136","author":"Y Sawalha","year":"2020","unstructured":"Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, et al. Outcomes of patients with relapsed mantle cell lymphoma treated with venetoclax: a multicenter retrospective analysis. Blood. 2020;136(Supplement 1):4\u20136.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1295_CR82","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2021-145421","volume":"138","author":"C Visco","year":"2021","unstructured":"Visco C, Tabanelli V, Peracchio C, Evangelista A, Tisi MC, Merli A, et al. Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma. Blood. 2021;138(Supplement 1):2427.","journal-title":"Blood."},{"issue":"12","key":"1295_CR83","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1038\/sj.leu.2403954","volume":"19","author":"E Galteland","year":"2005","unstructured":"Galteland E, Sivertsen EA, Svendsrud DH, Smedshammer L, Kresse SH, Meza-Zepeda LA, et al. Translocation t(14;18) and gain of chromosome 18\/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin\u2019s lymphomas. Leukemia. 2005;19(12):2313\u201323.","journal-title":"Leukemia"},{"issue":"S2","key":"1295_CR84","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hon.78_2629","volume":"37","author":"A Stathis","year":"2019","unstructured":"Stathis A, Mey U, Sch\u00e4r S, Hitz F, Pott C, Mach N, et al. SAKK 35\/15: a phase I trial of obinutuzumab in combination with venetoclax in previously untreated follicular lymphoma patients. Hematol Oncol. 2019;37(S2):118\u20139.","journal-title":"Hematol Oncol"},{"issue":"14","key":"1295_CR85","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331\u201344.","journal-title":"N Engl J Med"},{"issue":"9","key":"1295_CR86","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","volume":"29","author":"S de Vos","year":"2018","unstructured":"de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1932\u20138.","journal-title":"Ann Oncol"},{"issue":"18","key":"1295_CR87","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","volume":"133","author":"AD Zelenetz","year":"2019","unstructured":"Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019;133(18):1964\u201376.","journal-title":"Blood"},{"issue":"10","key":"1295_CR88","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934\u201347.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"1295_CR89","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1182\/blood-2021-145217","volume":"138","author":"CA Portell","year":"2021","unstructured":"Portell CA, Jegede O, Wagner-Johnston ND, Nowakowski GS, Fletcher CD, Cohen JB, et al. Phase II study of venetoclax in combination with obinutuzumab and bendamustine in patients with high tumor burden follicular lymphoma as front line therapy (PrECOG 0403). Blood. 2021;138(Supplement 1):814.","journal-title":"Blood."},{"issue":"23","key":"1295_CR90","first-page":"2628","volume":"136","author":"PL Zinzani","year":"2020","unstructured":"Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma. Blood. 2020;136(23):2628\u201337.","journal-title":"Blood"},{"issue":"5","key":"1295_CR91","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/cancers13051002","volume":"13","author":"RN Rys","year":"2021","unstructured":"Rys RN, Wever CM, Geoffrion D, Goncalves C, Ghassemian A, Brailovski E, et al. Apoptotic blocks in primary non-Hodgkin B cell lymphomas identified by BH3 profiling. Cancers (Basel). 2021;13(5):1002.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1295_CR92","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","volume":"13","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Martelli M, Trn\u011bn\u00fd M, Liu W, Bolen CR, Knapp A, et al. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13(1):71.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1295_CR93","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Ill\u00e9s \u00c1, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600\u20139.","journal-title":"Blood"},{"issue":"6","key":"1295_CR94","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjh.12982","volume":"166","author":"Y Oki","year":"2014","unstructured":"Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891\u2013901.","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"1295_CR95","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood-2021-151266","volume":"138","author":"JS Abramson","year":"2021","unstructured":"Abramson JS, Ruppert AS, Giri S, Hudson A, Hsi ED, Little RF, et al. Randomized phase II\/III Study of DA-EPOCH-R +\/- venetoclax in previously untreated double hit lymphoma: initial results from alliance A051701. Blood. 2021;138(Supplement 1):523.","journal-title":"Blood."},{"issue":"4","key":"1295_CR96","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.clml.2020.11.004","volume":"21","author":"E Punnoose","year":"2021","unstructured":"Punnoose E, Peale FV, Szafer-Glusman E, Lei G, Bourgon R, Do AD, et al. BCL2 expression in first-line diffuse large B-cell lymphoma identifies a patient population with poor prognosis. Clin Lymphoma Myeloma Leuk. 2021;21(4):267-78.e10.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"1295_CR97","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396\u2013407.","journal-title":"N Engl J Med"},{"key":"1295_CR98","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood.2021011386","volume":"139","author":"MS Davids","year":"2021","unstructured":"Davids MS, Rogers KA, Tyekucheva S, Ph D, Wang Z, Pazienza S, Renner SK, et al. Venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter\u2019s syndrome. Blood. 2021;139:686\u20139.","journal-title":"Blood"},{"issue":"12","key":"1295_CR99","doi-asserted-by":"publisher","first-page":"E239","DOI":"10.1002\/ajh.23841","volume":"89","author":"P Langerbeins","year":"2014","unstructured":"Langerbeins P, Busch R, Anheier N, D\u00fcrig J, Bergmann M, Goebeler ME, et al. Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014;89(12):E239\u201343.","journal-title":"Am J Hematol"},{"issue":"2","key":"1295_CR100","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.15035","volume":"180","author":"KA Rogers","year":"2018","unstructured":"Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, et al. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018;180(2):259\u201366.","journal-title":"Br J Haematol"},{"issue":"6","key":"1295_CR101","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2016-03-708263","volume":"128","author":"ZR Hunter","year":"2016","unstructured":"Hunter ZR, Xu L, Yang G, Tsakmaklis N, Vos JM, Liu X, et al. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstr\u00f6m macroglobulinemia. Blood. 2016;128(6):827\u201338.","journal-title":"Blood"},{"issue":"8","key":"1295_CR102","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2006-02-005488","volume":"108","author":"WJ Chng","year":"2006","unstructured":"Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006;108(8):2755\u201363.","journal-title":"Blood"},{"key":"1295_CR103","first-page":"JCo2101194","volume":"2021","author":"JJ Castillo","year":"2021","unstructured":"Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, et al. Venetoclax in previously treated Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2021;2021:JCo2101194.","journal-title":"J Clin Oncol."},{"issue":"1","key":"1295_CR104","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1182\/hematology.2020000157","volume":"2020","author":"A Broccoli","year":"2020","unstructured":"Broccoli A, Zinzani PL. How do we sequence therapy for marginal zone lymphomas? Hematology. 2020;2020(1):295\u2013305.","journal-title":"Hematology"},{"issue":"7","key":"1295_CR105","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","volume":"75","author":"SE Alford","year":"2015","unstructured":"Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, et al. BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 2015;75(7):1366\u201375.","journal-title":"Cancer Res"},{"issue":"10","key":"1295_CR106","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","volume":"128","author":"SL Khaw","year":"2016","unstructured":"Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 2016;128(10):1382\u201395.","journal-title":"Blood"},{"issue":"4","key":"1295_CR107","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","volume":"111","author":"MV Del Gaizo","year":"2008","unstructured":"Del Gaizo MV, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008;111(4):2300\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1295_CR108","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1182\/blood-2021-153826","volume":"138","author":"S Venugopal","year":"2021","unstructured":"Venugopal S, Kantarjian H, Short NJ, Thompson PA, Pemmaraju N, Jain N, et al. A phase II study of mini-hyper-CVD plus venetoclax in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2021;138(Supplement 1):1239.","journal-title":"Blood."},{"issue":"4","key":"1295_CR109","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, et al. Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(4):212\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1295_CR110","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/cancers14010150","volume":"14","author":"A Gibson","year":"2021","unstructured":"Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, et al. Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancers (Basel). 2021;14(1):150.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"1295_CR111","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11899-019-00501-3","volume":"14","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, Luger SM. Relapsed T Cell ALL: current approaches and new directions. Curr Hematol Malig Rep. 2019;14(2):83\u201393.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"1295_CR112","doi-asserted-by":"publisher","first-page":"Ijh02","DOI":"10.2217\/ijh-2017-0023","volume":"7","author":"Y Sawalha","year":"2018","unstructured":"Sawalha Y, Advani AS. Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. Int J Hematol Oncol. 2018;7(1):Ijh02.","journal-title":"Int J Hematol Oncol."},{"issue":"5","key":"1295_CR113","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","volume":"118","author":"AA Morales","year":"2011","unstructured":"Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells. Blood. 2011;118(5):1329\u201339.","journal-title":"Blood"},{"issue":"3","key":"1295_CR114","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2015.184","volume":"30","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30(3):761\u20134.","journal-title":"Leukemia"},{"issue":"5","key":"1295_CR115","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","volume":"15","author":"EA Punnoose","year":"2016","unstructured":"Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 Selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15(5):1132\u201344.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1295_CR116","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/leu.2013.216","volume":"28","author":"C Touzeau","year":"2014","unstructured":"Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210\u20132.","journal-title":"Leukemia"},{"issue":"26","key":"1295_CR117","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","volume":"137","author":"VA Gupta","year":"2021","unstructured":"Gupta VA, Barwick BG, Matulis SM, Shirasaki R, Jaye DL, Keats JJ, et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood. 2021;137(26):3604\u201315.","journal-title":"Blood"},{"issue":"5","key":"1295_CR118","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/leu.2015.350","volume":"30","author":"SM Matulis","year":"2016","unstructured":"Matulis SM, Gupta VA, Nooka AK, Hollen HV, Kaufman JL, Lonial S, et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia. 2016;30(5):1086\u201393.","journal-title":"Leukemia"},{"issue":"11","key":"1295_CR119","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","volume":"67","author":"P Gomez-Bougie","year":"2007","unstructured":"Gomez-Bougie P, Wuill\u00e8me-Toumi S, M\u00e9noret E, Trichet V, Robillard N, Philippe M, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 2007;67(11):5418\u201324.","journal-title":"Cancer Res"},{"issue":"3","key":"1295_CR120","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17(3):393\u2013403.","journal-title":"Mol Cell"},{"issue":"1","key":"1295_CR121","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41420-022-01009-1","volume":"8","author":"S Weller","year":"2022","unstructured":"Weller S, Toennie\u00dfen A, Schaefer B, Beigl T, Muenchow A, B\u00f6pple K, et al. The BCL-2 inhibitor ABT-199\/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA. Cell Death Discov. 2022;8(1):215.","journal-title":"Cell Death Discov"},{"issue":"22","key":"1295_CR122","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401\u20139.","journal-title":"Blood"},{"issue":"4","key":"1295_CR123","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","volume":"96","author":"JL Kaufman","year":"2021","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. Am J Hematol. 2021;96(4):418\u201327.","journal-title":"Am J Hematol"},{"issue":"22","key":"1295_CR124","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","volume":"130","author":"P Moreau","year":"2017","unstructured":"Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM. Blood. 2017;130(22):2392\u2013400.","journal-title":"Blood"},{"issue":"19","key":"1295_CR125","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","volume":"5","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2021;5(19):3748\u201359.","journal-title":"Blood Adv"},{"issue":"32","key":"1295_CR126","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol. 2021;39(32):3602\u201312.","journal-title":"J Clin Oncol"},{"key":"1295_CR127","doi-asserted-by":"publisher","first-page":"1610276","DOI":"10.3389\/pore.2022.1610276","volume":"28","author":"VR Szita","year":"2022","unstructured":"Szita VR, Mikala G, Kozma A, F\u00e1bi\u00e1n J, Hardi A, Alizadeh H, et al. Targeted venetoclax therapy in t(11;14) multiple myeloma: real world data from seven Hungarian centers. Pathol Oncol Res. 2022;28:1610276.","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"1295_CR128","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ejh.12986","volume":"100","author":"WI Gonsalves","year":"2018","unstructured":"Gonsalves WI, Buadi FK, Kumar SK. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). Eur J Haematol. 2018;100(2):215\u20137.","journal-title":"Eur J Haematol"},{"key":"1295_CR129","first-page":"8823877","volume":"2020","author":"S Valliani","year":"2020","unstructured":"Valliani S, Ali M, Mahmoo O, Hinduja S, Chen CK, Damon L, et al. Efficacy of venetoclax and dexamethasone in refractory IgM primary plasma cell leukemia with t(11;14) and TP53 mutation: a case report and literature review. Case Rep Hematol. 2020;2020:8823877.","journal-title":"Case Rep Hematol"},{"issue":"Supplement 1","key":"1295_CR130","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1182\/blood-2021-145757","volume":"138","author":"S Kumar","year":"2021","unstructured":"Kumar S, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto CJ, et al. Final overall survival results from BELLINI, a Phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma. Blood. 2021;138(Supplement 1):84.","journal-title":"Blood."},{"issue":"12","key":"1295_CR131","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630\u201342.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"1295_CR132","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1182\/blood-2019-126094","volume":"134","author":"S Harrison","year":"2019","unstructured":"Harrison S, Cavo M, De La Rubia J, Popat R, Gasparetto C, Hungria VTM, et al. T(11;14) and high BCL2 expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: biomarker analyses from the Phase 3 Bellini study. Blood. 2019;134(Suppl 1):142.","journal-title":"Blood."},{"issue":"Supplement 1","key":"1295_CR133","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2021-146012","volume":"138","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Kaufman JL, Baz R, Quach H, Ho S-J, Vangsted AJ, et al. Rapid and sustained reduction of immunosuppressive T-cells and focusing of the T-Cell repertoire in t(11;14) relapsed\/refractory multiple myeloma patients treated with venetoclax in combination with daratumumab and dexamethasone. Blood. 2021;138(Supplement 1):1633.","journal-title":"Blood."},{"issue":"1","key":"1295_CR134","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, et al. Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 2021;11(1):68\u201379.","journal-title":"Cancer Discov"},{"issue":"11","key":"1295_CR135","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41419-021-04285-4","volume":"12","author":"LM Ludwig","year":"2021","unstructured":"Ludwig LM, Hawley KM, Banks DB, Thomas-Toth AT, Blazar BR, McNerney ME, et al. Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. Cell Death Dis. 2021;12(11):1005.","journal-title":"Cell Death Dis"},{"issue":"26","key":"1295_CR136","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1182\/blood.2019004492","volume":"135","author":"E Tausch","year":"2020","unstructured":"Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020;135(26):2402\u201312.","journal-title":"Blood"},{"issue":"25","key":"1295_CR137","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127(25):3215\u201324.","journal-title":"Blood"},{"issue":"20","key":"1295_CR138","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood.2020010167","volume":"137","author":"R Thijssen","year":"2021","unstructured":"Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, et al. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021;137(20):2721\u201335.","journal-title":"Blood"},{"issue":"4","key":"1295_CR139","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Guieze","year":"2019","unstructured":"Guieze R, Liu VM, Rosebrock D, Jourdain AA, Hernandez-Sanchez M, Martinez Zurita A, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36(4):369\u201384.","journal-title":"Cancer Cell."},{"issue":"1","key":"1295_CR140","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","volume":"9","author":"CD Herling","year":"2018","unstructured":"Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018;9(1):727.","journal-title":"Nat Commun"},{"issue":"6","key":"1295_CR141","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1111\/bjh.16069","volume":"186","author":"P Blombery","year":"2019","unstructured":"Blombery P, Birkinshaw RW, Nguyen T, Gong JN, Thompson ER, Xu Z, et al. Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. Br J Haematol. 2019;186(6):e188\u201391.","journal-title":"Br J Haematol"},{"issue":"10","key":"1295_CR142","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1182\/blood.2019004205","volume":"135","author":"P Blombery","year":"2020","unstructured":"Blombery P, Thompson ER, Nguyen T, Birkinshaw RW, Gong JN, Chen X, et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood. 2020;135(10):773\u20137.","journal-title":"Blood."},{"issue":"24","key":"1295_CR143","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1182\/blood.2019003722","volume":"135","author":"F Lucas","year":"2020","unstructured":"Lucas F, Larkin K, Gregory CT, Orwick S, Doong TJ, Lozanski A, et al. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations. Blood. 2020;135(24):2192\u20135.","journal-title":"Blood"},{"issue":"9","key":"1295_CR144","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","volume":"104","author":"E Tausch","year":"2019","unstructured":"Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019;104(9):e434\u20137.","journal-title":"Haematologica"},{"key":"1295_CR145","first-page":"15","volume":"136","author":"ER Thompson","year":"2020","unstructured":"Thompson ER, Nguyen T, Kankanige Y, Anderson MA, Handunnetti SM, Thijssen R, et al. High clonal complexity of resistance mechanisms occurring at progression after single-agent targeted therapy strategies in chronic lymphocytic leukemia. Blood. 2020;136:15\u20136.","journal-title":"Blood"},{"issue":"8","key":"1295_CR146","first-page":"e302","volume":"100","author":"R Thijssen","year":"2015","unstructured":"Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100(8):e302.","journal-title":"Haematologica"},{"issue":"25","key":"1295_CR147","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","volume":"129","author":"MA Anderson","year":"2017","unstructured":"Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017;129(25):3362\u201370.","journal-title":"Blood"},{"key":"1295_CR148","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1182\/blood.2020004782","volume":"135","author":"VS Lin","year":"2020","unstructured":"Lin VS, Lew TE, Handunnetti SM, Blombery P, Nguyen T, Westerman DA, et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood. 2020;135:2266\u201370.","journal-title":"Blood."},{"key":"1295_CR149","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005357","author":"CA Portell","year":"2021","unstructured":"Portell CA, Wages NA, Kahl BS, Budde LE, Chen RW, Cohen JB, et al. Dose finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. Blood Adv. 2021. https:\/\/doi.org\/10.1182\/bloodadvances.2021005357.","journal-title":"Blood Adv."},{"issue":"Supplement 1","key":"1295_CR150","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood-2020-134446","volume":"136","author":"WG Wierda","year":"2020","unstructured":"Wierda WG, Tam CS, Allan JN, Siddiqi T, Kipps TJ, Opat S, et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study. Blood. 2020;136(Supplement 1):16\u20137.","journal-title":"Blood"},{"issue":"7","key":"1295_CR151","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"1295_CR152","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137\u201345.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1295_CR153","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2021-150914","volume":"138","author":"AH Lipsky","year":"2021","unstructured":"Lipsky AH, Hill BT, Winter AM, Jurcic JG, Heaney ML, Rosenblat TL, et al. High rates of undetectable minimal residual disease remissions with time-limited bendamustine, rituximab, and venetoclax (BR-VR) in untreated chronic lymphocytic leukemia (CLL). Blood. 2021;138(Supplement 1):1555.","journal-title":"Blood."},{"key":"1295_CR154","doi-asserted-by":"publisher","first-page":"e818","DOI":"10.1016\/S2352-3026(21)00273-8","volume":"8","author":"SC Rutherford","year":"2021","unstructured":"Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, et al. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet Haematol. 2021;8:e818\u201327.","journal-title":"Lancet Haematol."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01295-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01295-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01295-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T12:25:16Z","timestamp":1654259116000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01295-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":154,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01295-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"11 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T.E.L. is an employee of the Walter and Eliza Hall Institute of Medical Research, which receives milestone and royalty payments related to venetoclax, is a recipient of a share in royalty payments paid to the Walter and Eliza Hall Institute of Medical Research and has received honoraria from AbbVie. J.F.S. has received research funding from AbbVie, Genentech, Celgene and Janssen and is an advisory board member for and has received honoraria from AbbVie, Acerta, Celgene, Genentech, Janssen, Roche, Sunesis and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}